Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NZQ7

UPID:
PD1L1_HUMAN

ALTERNATIVE NAMES:
B7 homolog 1

ALTERNATIVE UPACC:
Q9NZQ7; B2RBA2; B4DU27; Q14CJ2; Q2V8D5; Q66RK1; Q6WEX4; Q9NUZ5

BACKGROUND:
The interaction of Programmed cell death 1 ligand 1 (PD-L1) with its receptor PDCD1/PD-1 inhibits cytotoxic T lymphocyte function, a mechanism exploited by tumors to suppress anti-tumor immunity. This protein, also known as B7 homolog 1, is instrumental in maintaining immune system balance by modulating T-cell activation and effector responses.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Programmed cell death 1 ligand 1 could open doors to potential therapeutic strategies. Its involvement in the PD-L1/PDCD1 inhibitory pathway presents a target for cancer immunotherapy, aiming to block this interaction to restore effective anti-tumor immunity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.